All News
New Year's Resolutions (1.5.2024)
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).
Read Article
Curcumin therapy for knee osteoarthritis
Curcumin is widely used in traditional Chinese medicine to treat arthritis and is presumed to have analgesic and antiinflammatory effects that may benefit those with osteoarthritis, particularly knee osteoarthritis (KOA).
Read Article
Does Weight Loss Really Work in Gout?
A clinical trial has shown that obese gout patients will benefit from diet and lowered body weight, but weight loss was not associated with beneficial effects on serum urica acid (SUA), fatigue or pain.
Read Article
Sarcopenia Linked to Smoking in Osteoarthritis
Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.
https://t.co/anZMTGnFej https://t.co/TgVg3xpiWI
Dr. John Cush RheumNow ( View Tweet)
Biomarker Predicts Survival in Autoimmune Lung Disease
One major subgroup of patients with ILD arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.
https://t.co/PcTmzavJuC https://t.co/cNL3iTSGiF
Dr. John Cush RheumNow ( View Tweet)
Sarcopenia Linked to Smoking in Osteoarthritis
Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.
https://t.co/ucEWJjZ8Zv https://t.co/MeHw56vLjj
Dr. John Cush RheumNow ( View Tweet)
GNSC-001 gene therapy w/ a recombinant adeno-assoc. viral vector expressing IL-1Ra, to block IL-1. GNSC-001 now in a phase Ib, 50 pt, 10 center USA trial to assess its efficacy in Knee OA. Given as single injx in the affected joint; results in late 2024 https://t.co/jW9FHlGyC2 https://t.co/Dbv15Flqlv
Links:
Dr. John J Cush RheumNow ( View Tweet)
Cross-sectional study of 307 RA pts, 49 (16%) used psychotropic meds and 70 (23%) had at least one fall per year. RA on psychotropic meds had double the rate of falls (39% vs 20%). w/ an adjusted incidence rate ratio, 1.63. (p = 0.02). https://t.co/D1lhZj3he3
Dr. John Cush RheumNow ( View Tweet)
New download on ChatGPT available!
https://t.co/mZc5Ex2vU9 https://t.co/DyfZepwFOD
Links:
Dr. John Cush RheumNow ( View Tweet)
Do I have Arthritis?
How I handle this frequent curbside consult question...
https://t.co/uX6MUfy59w https://t.co/kYviOhcLQj
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of CNS Lupus, 44 studies, 17 865 early- (<50y) vs 2970 late-onset SLE (>50y) pts. CNS LE in 16%, more common in younger LE (OR: 1.41). Early-LE had more seizures (OR: 1.68), psychosis (OR: 1.72). Older - more Peripheral neuropathy (OR: 0.64) https://t.co/XoJjIH69t6 https://t.co/sRyV7A07gA
Dr. John Cush RheumNow ( View Tweet)
Biomarker Predicts Survival in Autoimmune Lung Disease
One major subgroup of patients with ILD arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.
https://t.co/9c9DjOIeoI https://t.co/fBpvjODybd
Dr. John Cush RheumNow ( View Tweet)
In Norway incidence of #SLE is decreasing, esp in women 50-59 years. Population study of 1558 confirmed SLE; 797 had new-onset betw 1999-2017. In older women 50-59 yrs incidence fell 3.4 to 1.1/100K (also 74% reduction in menopausal HRT https://t.co/Z1falNwLlD https://t.co/bJ3cXKueKg
Dr. John Cush RheumNow ( View Tweet)
Small study of 33 #AAV pts and 21 controls shows nailfold capillaroscopy of no value in diagnosing/assessing AAV pts. https://t.co/uRFDBbLVJq https://t.co/pVETSFlBsp
Dr. John Cush RheumNow ( View Tweet)
Poorly documented Dz activity in SpA. AI EHR analysis of 3 Hospitals found 758 pts (328 axSpA, 365 PsA, 65 non-classified SpA). Only 35% axSpA had ASDAS or BASDAI. DAPSA or DAS-28 in only 17% PsA. TJC/SJC in ~20% axSpA & ~32% of PsA https://t.co/OrLdK5k2lN https://t.co/bKjancBG4r
Dr. John Cush RheumNow ( View Tweet)
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest
https://t.co/zJ9583vllj https://t.co/M1oKAcnqSH
Dr. John Cush RheumNow ( View Tweet)
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/RdLUvW3W7v https://t.co/CcQXQYwu7J
Dr. John Cush RheumNow ( View Tweet)
Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y
Dr. John Cush RheumNow ( View Tweet)
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/uRYKmtUdsZ https://t.co/5XdBVDfgYV
Dr. John Cush RheumNow ( View Tweet)